Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.

BMC nephrology - 10 Mar 2021

Kim Mi Jung, Lee Haekyung, Kim Yon Hee, Jin So Young, Kim Hee-Jin, Oh Doyeun, Jeon Jin Seok

Abstract excerpt

BACKGROUND: Thrombotic microangiopathy (TMA), a rare but serious complication of systemic lupus erythematosus (SLE), is associated with poor outcomes to conventional immunosuppressive therapy. Recently, eculizumab, a humanised monoclonal antibody that blocks the complement factor 5, has been known to effectively treat atypical haemolytic uremic syndrome (aHUS). Here, we report a case of aHUS co-existing with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C3

Share to Lupus Nephritis

Share to Mutation

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33691638
DOI: 10.1186/s12882-021-02293-2
PMCID: PMC7944615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.PMID 33691638Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

[Atypical hemolytic uremic syndrome].Semantic proximity Read ↗

Consensus regarding diagnosis and management of atypical hemolytic uremic syndromeSemantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab.Semantic proximity Read ↗

C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: Laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations.Semantic proximity Read ↗

How I diagnose and treat atypical hemolytic uremic syndromeSemantic proximity Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.